Aberrant expression of CC and CXC chemokines and their receptors in patients with asthma.

Authors: Lun, SW  Wong, CK  Ko, FW  Ip, WK  Hui, DS  Lam, CW 
Citation: Lun SW, etal., J Clin Immunol. 2006 Mar;26(2):145-52. Epub 2006 Apr 7.
Pubmed: (View Article at PubMed) PMID:16602032
DOI: Full-text: DOI:10.1007/s10875-006-9003-9

This study further elucidates the roles of selected chemokines (IP-10, MIG, and RANTES) and their receptors (CCR3, CCR5, and CXCR3) in asthma. We compared their profiles in six groups of participants-atopic cohort and nonatopic cohort (each including controls and asthmatic patients with or without steroid therapy). Plasma concentration of IP-10 was significantly lower while that of RANTES and the expression of CCR3 were higher in asthmatic patients (all p < 0.05). Plasma RANTES correlated positively with the GINA severity score in all asthmatic patients (r=0.27, p < 0.05), and with IL-13 in nonatopic asthmatic patients (r=0.46, p < 0.05). In asthmatic patients, the ex vivo release of IP-10 and MIG was attenuated in PBMC activated with allergen, mitogens and IL-18 (p < 0.05). In conclusion, plasma RANTES may be a surrogate marker for asthma and the diminished Th1 related CXC chemokine production may contribute to Th2 predominance in asthma.

Annotation

Disease Annotations
RGD Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 5135457
Created: 2011-07-21
Species: All Species
Last Modified: 2011-07-21
Status: ACTIVE